Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4
Abstract
Several reports in the literature have drawn a complex picture of the effect of treatments aiming to modulate IL2 activity in vivo. They seem to promote either immunity or tolerance, probably depending on the specific context, dose and timing of their application. Such complexity might derive from the pleotropic role of IL2 in T cell dynamics. To theoretically address the latter possibility, our group has developed several mathematical models for Helper, Regulatory and Memory T cell population dynamics, which account for most well-known facts concerning their relationship with IL2. We have simulated the effect of several types of therapies, including the injection of: IL2; antibodies anti-IL2; IL2/anti-IL2 immune complexes and mutant variants of IL2. We studied the qualitative and quantitative conditions of dose and timing for these treatments which allow them to potentiate either immunity or tolerance. Our results provide reasonable explanations for the existent pre-clinical and clinical data, predict some novel treatments, and further provide interesting practical guidelines to optimize the future application of these types of treatments.Keywords
This publication has 49 references indexed in Scilit:
- Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell CarcinomaJournal of Immunotherapy, 2008
- A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virusVaccine, 2007
- DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activityImmunology Letters, 2007
- Interleukin‐2 Mastering Regulation in Cancer and AutoimmunityAnnals of the New York Academy of Sciences, 2007
- Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activityCancer Immunology, Immunotherapy, 2007
- IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patientsBlood, 2006
- Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cellsBlood, 2002
- Increased peripheral expansion of naive CD4+ T cellsin vivoafter IL-2 treatment of patients with HIV infectionProceedings of the National Academy of Sciences, 2002
- Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral TherapyJAMA, 2000
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1996